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Abstract
Background: Multiple myeloma is an incurable disease requiring the development of effective therapies which can
be used clinically. We have elucidated the potential for manipulating the cAMP signaling pathway as a target for
inhibiting the growth of multiple myeloma cells.
Methods: As a model system, we primarily used the murine multiple myeloma cell line MOPC315 which can be
grown both in vivo and in vitro. Human multiple myeloma cell lines U266, INA-6 and the B-cell precursor acute
lymphoblastic leukemia cell line Reh were used only for in vitro studies. Cell death was assessed by flow cytometry
and western blot analysis after treatment with cAMP elevating agents (forskolin, prostaglandin E2 and rolipram)
and cAMP analogs. We followed tumor growth in vivo after forskolin treatment by imaging DsRed-labelled
MOPC315 cells transplanted subcutaneously in BALB/c nude mice.
Results: In contrast to the effect on Reh cells, 50 μM forskolin more than tripled the death of MOPC315 cells after
24 h in vitro. Forskolin induced cell death to a similar extent in the human myeloma cell lines U266 and INA-6.
cAMP-mediated cell death had all the typical hallmarks of apoptosis, including changes in the mitochondrial
membrane potential and cleavage of caspase 3, caspase 9 and PARP. Forskolin also inhibited the growth of
multiple myeloma cells in a mouse model in vivo.
Conclusions: Elevation of intracellular levels of cAMP kills multiple myeloma cells in vitro and inhibits development
of multiple myeloma in vivo. This strongly suggests that compounds activating the cAMP signaling pathway may
be useful in the field of multiple myeloma.
Background
Multiple myeloma (MM) is a B-cell malignancy charac-
terized by accumulation of plasma cells in the bone
marrow, osteolytic bone lesions, and immunodeficiency
[1]. It accounts for ~10% of hematological malignancies
[2] with a median survival of 4 years [3]. Despite the
progress made the last decades in the development of
new therapies, multiple myeloma remains an incurable
disease for which a constant search for new treatment
strategies must continue.
Cyclic adenosine monophosphate (cAMP) is an intra-
cellular messenger formed in response to diverse extra-
cellular stimuli including hormones or
neurotransmitters. It is generated from ATP by adeny-
lyl cyclases, and is degraded by phosphodiesterases
(PDE) into adenosine-5’-monophosphate. The main
targets of cAMP are protein kinase A (PKA) [4],
cAMP-gated ion channels [5] and exchange proteins
directly activated by cAMP (EPAC) [6]. cAMP affects
numerous cellular processes, such as cell differentia-
tion, cell cycle progression and apoptosis, both in a
PKA-dependent and PKA-independent manner [7-9].
In many cancer tissues and cell lines, alterations in
cAMP signaling pathway including changes in intracel-
lular levels of cAMP [10,11] and PKA isoforms ratio
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switch [12-15], have been observed. Consequently,
there is a growing interest in manipulating the cAMP
signaling pathway as a strategy for the treatment of
cancer, and in particular a renewed interest for the
potential of combining PDE inhibitors and glucocorti-
coids for treatment of hematological malignancies [16].
We have previously shown that cAMP blocks the G1/
S phase transition and DNA synthesis in lymphoid cells
[17-19]. More recently, we demonstrated that elevation
of intracellular cAMP alone has no effect on cell death
in B-cell precursor acute lymphoblastic leukemia (BCP-
ALL) cells, but that it prevents apoptosis and accumula-
tion of p53 in the cells subjected to g-irradiation (g-IR)
[20]. In the present paper, we have explored the role of
cAMP in multiple myeloma by primarily using the mul-
tiple myeloma cell line MOPC315. This cell line was
chosen as it is a suitable mouse model [21,22] for study-
ing the effect of cAMP on development of multiple
myeloma in vivo. Elevation of intracellular levels of
cAMP in the multiple myeloma cells did not prevent g-
IR-mediated death of the cells in vitro, but interestingly,
cAMP alone efficiently killed the myeloma cells. More
importantly, we could demonstrate that cAMP prevents
the growth of multiple myeloma cells in vivo.
Methods
Chemicals, Antibodies
Forskolin and rolipram (Sigma; Saint Louis, MO, USA)
were diluted in dimethyl sulfoxide (DMSO), 8CPT-
cAMP (Biolog, Bremen, Germany) was diluted in dis-
tilled water, whereas prostaglandin E2 (Cayman, Ann
Arbor, MI, USA) was diluted in ethanol. Propidium
iodide, DMSO, saponin, paraformaldehyde and bovine
serum albumin (BSA) were purchased from Sigma. The
cationic fluorescent carbocyanine dye 5,5’,6,6’-Tetra-
chloro-1,1’,3,3’ -tetraethylbenzimidazolylcarbocyanine
iodide (JC-1) was from Calbiochem (San Diego, CA,
USA).
Antibodies against caspase 3 (8G10), caspase 9 (the
mouse-specific 9504 and the human-specific 9502) and
PARP were purchased from Cell Signaling Technologies
(Danvers, MA, USA). P53 (fl393) antibody was pur-
chased from Santa Cruz Biotechnology (Fremont, CA,
USA). Antibody against GAPDH (Sigma) was used as a
loading control. Anti-goat and anti-mouse HRP-conju-
gated secondary antibodies were purchased from Bio-
Rad (Hercules, CA, USA).
Irradiation of the cells
Cells were irradiated using a 137Cs source at 4.3 Gy/min.
Cell lines and cell culture
The BCP-ALL cell line Reh [23] was cultured as pre-
viously described [19]. The transplantable BALB/c
mineral oil-induced plasmacytoma cell line, MOPC315
[21], was used to generate a subline, MOPC315.4, that
grew well in vitro and in vivo [24]. A subline of
MOPC315.4, MOPC315.BM (Bogen et al., unpublished),
was used for the present experiments. Some experi-
ments employed MOPC315.BM labeled with the fluores-
cent protein DsRed. For simplicity, the MOPC315.BM
subline will be referred to as MOPC315 throughout the
paper. The cells were cultured in vitro in RPMI 1640
(Invitrogen, Paisley, UK) containing 2 mM L-glutamine,
supplemented with MEM non essential amino acid
(Sigma), 1 mM sodium pyruvate (Sigma), 50 μM mono-
thioglycerol (Sigma), 12 μg/ml gentamycin (Sigma) and
10% heat-inactivated FBS (Lonza, Verviers, Belgium).
The human multiple myeloma cell line, INA-6 cells, was
a kind gift from Dr. M. Gramatzki (Erlangen, Germany)
and were cultured in RPMI 1640 (Invitrogen) containing
2 mM L-glutamine (Invitrogen), supplemented with 1
ng/ml Il-6 (Invitrogen), 12 μg/ml gentamycin (Sigma)
and 10% heat-inactivated FBS (Lonza). The U266 cell
line was purchased from the American Type Culture
Collection (ATCC, Manassas, VA, USA) and was cul-
tured in RPMI 1640 (Invitrogen) containing 2 mM L-
glutamine (Invitrogen), supplemented with 15% heat-
inactivated FBS (Sigma), 100 U/ml penicillin (Invitro-
gen), and 100 μg/ml streptomycin (Invitrogen).
Flow cytometry
Flow cytometry analysis was performed on a FACS Cali-
bur (Becton-Dickinson). For determination of cell viabi-
lity by exclusion of propidium iodide (PI), 500 μl of cell
culture were incubated with 20 μg/ml PI for 10 min at
room temperature prior to analysis. The cationic fluor-
escent carbocyanine dye, 5,5’,6,6’-tetrachloro-1,1’,3,3’
-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) was
used to assess changes in the mitochondrial membrane
potential (ΔΨm) observed in apoptotic cells. Cells were
incubated for 15 min at 37°C with 15 μg/ml JC-1 before
analysis. For determination of apoptotic cells, TUNEL
assays were performed by using an In Situ Cell Death
Detection Kit, Fluorescein from Roche (Mannheim, Ger-
many). Briefly, cells were washed in ice cold PBS before
being fixed with 4% paraformaldehyde and permeabi-
lized with 0,1% saponin. Cells were washed in ice cold
PBS before incubation in the TUNEL reaction mix for 1
h at 37°C. After washing the cells 3 times, the cells were
analyzed by flow cytometry.
Immunoblot analysis
Cells were lysed in RIPA buffer (50 mM Tris [pH7.5],
150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5 mM EDTA, 50
mM NaF, 10 mM b-glycerophosphate, 1 mM Na3VO4,
0.2 mM phenylmethylsulfonyl fluoride [PMSF], 10 μg/
ml leupeptin, and 0.5% aprotinin) and an equal amount
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of proteins (50 μg) was separated by SDS-PAGE (Bio-
Rad) electrophoresis. After transfer to a nitrocellulose
membrane (GE Healthcare) using a semidry transfer cell
(Bio-Rad), proteins were detected by standard immuno-
blotting procedures. In brief, the nitrocellulose mem-
branes were washed in Tris buffered saline and 0.1%
Tween (TBST) and incubated in blocking solution (5%
non-fat dry milk in TBST or 5% BSA in TBST) at room
temperature. After washing, the membranes were incu-
bated overnight at 4°C with primary antibodies diluted
in blocking solution. After washing in TBST, the mem-
branes were incubated for 1 h with HRP-conjugated sec-
ondary antibody diluted in blocking solution, followed
by a final washing at room temperature. Immunoreac-
tive proteins were visualized with the enhanced chemilu-
minescence detection system (ECL, Amersham
Pharmacia Biotech, UK) or the SuperSignal® west Dura
Extended Duration substrate (Thermo Scientific, Rock-
ford, IL, USA) according to the manufacturer’s protocol.
Mouse model for multiple myeloma
Adult BALB/c nude mice (purchased from Charles
River, Germany) were injected subcutaneously in the
interscapular region with 5 × 105 tumor MOPC315.
DsRed cells suspended in 100 μL PBS. Two days after
injection of the cells, 5 mice were injected intraperitone-
ally with 4-5 mg/kg forskolin diluted in a PBS/DMSO
solution (15:0.1), and 5 mice were injected with the
vehicle. In a separate experiment, forskolin (or vehicle)
was injected 3 times on days 2, 4 and 6. Tumor growth
was followed daily by palpation and imaging. Mice with
tumor diameters of 15-20 mm were killed by cervical
dislocation. The study was approved by the National
Committee for Animal Experiments.
In vivo imaging of mice
Mice were anaesthetized with 2.5% isoflurane (Baxter
As, Norway). Immediately afterwards, they were placed
in a light-sealed imaging chamber and kept anaesthe-
tized throughout the imaging period.
Images were acquired using a combination of excita-
tion (30 nm passband) and emission (20 nm passband)
filters on an IVIS Spectrum Imaging System (Caliper
Life Sciences). The following spectral channels were
used (excitation:emission center wavelength in nm):
465:540, 465:580, 535:600 and 570:620. Spectral images
were recorded in units of photons/second/cm2/sr and
imported as 32 bit floating point TIFF files into Mathe-
matica 5.2 (Wolfram Research) for further processing.
Images were scaled with an excitation light correction
factor [25] yielding normalized fluorescence efficiency
(NFE) images for further processing. Background refer-
ence autofluorescence spectrum was recorded from the
interscapular region on day 0 before MOPC315
injection. A reference MOPC315.DsRed spectrum was
determined from a region containing a localized tumor
(day 5) with the reference autofluorescence subtracted.
MOPC315.DsRed specific signal was determined by lin-
ear (pseudo-inverse) unmixing [26], yielding DsRed
fluorescence maps, which were thresholded, intensity
color-coded and overlaid a white light illuminated
image. Quantification of MOPC315.DsRed fluorescence
was done by computing the total DsRed fluorescence
for above-threshold pixels for each animal.
Statistical analysis
The paired-samples t-test was applied to check the sig-
nificance in cell line experiments, using the PASW Sta-
tistic 18 software for windows. In all the figures,
histograms show mean values of the indicated number
of experiments, with error bars corresponding to SEM
values. For in vivo experiments, the Wilcoxon signed-
rank test was used to determine significant differences
between 2 groups of mice.
Results
Elevation of cAMP levels by forskolin induces death of
multiple myeloma cells
We have previously shown that in B-cell precursor acute
lymphoblastic leukemia (BCP-ALL) cells, elevated intra-
cellular levels of cAMP prevent apoptosis induced by a
variety of DNA-damaging cytotoxic agents, including
ionizing radiation (IR). We have also demonstrated that
destabilization of p53 is a key feature in this process
[20]. Now we have compared the effects of the adenylyl
cyclase-activating diterpine forskolin [27] on IR-
mediated cell death of the BCP-ALL cell line Reh and
the plasmacytoma cell line MOPC315. Figure 1A (left
panel) shows that forskolin (50 μM) alone had no effect
on the viability of the Reh cells, but unsurprisingly pre-
vented IR-induced apoptosis, as measured 24 h later. In
sharp contrast, forskolin did not prevent IR-mediated
death of the myeloma cells (Figure 1A, right panel), but
rather potentiated the effect of irradiation. More intrigu-
ingly, after 24 hours of sole forskolin treatment, the per-
centage of dead MOPC315 cells increased from ~16% to
~50%.
To confirm the differential effect of forskolin on IR-
treated Reh cells and MOPC315 cells, the effect of ele-
vating cAMP on p53 expression was analyzed. In accor-
dance with our previous result [20], forskolin prevented
the IR-induced stabilization of p53 in Reh cells (Figure
1B). In contrast forskolin had no effect on p53 induced
by IR in MOPC315 cells. Importantly, forskolin alone
decreased the p53 levels in MOPC315 cells, indicating
that induction of p53 is not involved in cAMP-mediated
cell death of MOPC315 cells. Myeloma cells were nota-
bly more sensitive to irradiation than Reh cells; only 2
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Gy was used to obtain similar death in MOPC315 cells
compared to 10 Gy in Reh cells.
Dose- and time-dependent effects of forskolin on death
of MOPC315 cells are mediated via cAMP
MOPC315 cells were treated for 24 h with increasing
doses of forskolin, or with 50 μM of forskolin, at various
time points. Cell death was measured by incorporation
of PI. Forskolin induced death of MOPC315 cells was
both dose- and time-dependent (Figure 2A and 2B,
respectively). Death occurred at doses as low as 0.1 μM
forskolin, and statistically significant death could be
detected already after 8 h with 50 μM forskolin.
In addition to the activation of adenylyl cyclase, for-
skolin has been reported to modulate other cellular pro-
cesses, such as ion channels [28,29]. We tested the
effect of other cAMP increasing agents to verify that
forskolin-induced cell death was mediated by
intracellular accumulation of cAMP. This included the
cell membrane permeable cAMP analog 8-chlorophe-
nylthio-cAMP (8CPT-cAMP) and prostaglandin E2
(PGE2), which increases intracellular levels of cAMP
through the activation G-protein-coupled receptors
[30,31]. MOPC315 cells were killed in a dose-dependent
manner by 8CPT-cAMP or PGE2 (Figure 2C and 2D,
respectively), supporting the notion that forskolin kills
the MOPC315 cells via induction of cAMP.
cAMP induces death of human multiple myeloma cells
To verify that the killing of murine multiple myeloma
cells by cAMP was applicable to human myeloma cells,
the human multiple myeloma cell line U266 and the IL-
6-dependent human myeloma cell line INA-6 were
included. The cells were treated for 24 h with increasing
doses of forskolin or 8CPT-cAMP, and cell death was
assessed by PI incorporation. Both human multiple
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Figure 1 Effect of forskolin on DNA-damaged induced cell death. Vehicle or 50 μM forskolin was added to cell cultures 30 min prior to
exposure of Reh cells and MOPC315 cells to 10Gy and 2Gy, respectively. (A) 24 h after irradiation, cell death was assessed by PI staining. The
results represent the mean values +/- SEM of 3 (Reh cells) or 6 (MOPC315 cells) experiments respectively. *P < 0.05 relative to cells treated with
vehicle. (B) 4 h after irradiation, cells were harvested and examined for p53 and GAPDH expression by Western blot analysis.
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myeloma cell lines were sensitive to intracellular eleva-
tion of cAMP (Figure 3A, B and 3C), indicating that ele-
vation of intracellular levels of cAMP indeed also
induces cell death in human multiple myeloma cells. By
using a cAMP Biotrack enzymeimmunoassay (EIA), we
verified that forskolin increased the intracellular cAMP
concentrations in these two cell lines (data not shown).
To further confirm the involvement of the cAMP signal-
ing pathway in killing multiple myeloma cells, INA-6
cells were treated for 24 hours with a low dose of
forskolin in combination with rolipram, an inhibitor of
PDE4. Rolipram or a low dose of forskolin alone
induced little or no cell death, whereas a combination of
the two compounds markedly increased cell death (Fig-
ure 3D).
cAMP induces apoptotic cell death in multiple myeloma
cells
To ascertain whether cAMP induces cell death by apopto-
sis, MOP315 cells treated with forskolin or 8CPT-cAMP
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Figure 2 cAMP induces cell death in MOPC315 cells. MOPC315 cells were incubated for 24 h with the indicated concentrations of forskolin
(A), with vehicle (open circles) or 50 μM forskolin (closed circles) for the indicated incubation times (B), or with the stated concentrations of 8-
CPT-cAMP (C) or prostaglandin E2 (D) for 24 h. Cell death was measured by PI-staining, and the results are presented as percentage of PI-
positive cells +/-SEM. A,C and D, n = 4; B, n = 3. *P < 0.05 relative to cells treated with vehicle.
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were analyzed for DNA fragmentation by TdT-mediated
dUTP nick end labeling (TUNEL) technique, or by analy-
sis of changes in mitochondrial membrane potential (Δ
Ψm) by staining the cells with JC-1. Forskolin and 8CPT-
cAMP induced similar percentage of dead cells whether
cell death was measured as percentage of cells with frag-
mented DNA (TUNEL assay), by changes in mitochon-
drial membrane potential (JC-1 staining), or by simple
incorporation of PI (Figure 4A), clearly suggesting that
cAMP induces apoptotic death of multiple myeloma cells.
To verify cAMP induced death of myeloma cells to be
apoptoic, we investigated the downstream events
following mitochondrial depolarization. Mitochondrial
outer membrane permeabilization results in the release
of cytochrome C from the intermembrane space into
the cytosol, triggering the assembly of the caspase-acti-
vating complex that mediates autocleavage and activa-
tion of caspase 9 [32]. Once activated, caspase 9
activates downstream effector caspases such as caspase
3 provoking the cleavage of several proteins, such as
PARP, which ultimately leads to cell destruction [33].
MOPC315 cells and INA-6 cells were treated with 50
μM forskolin or vehicle, and expression of cleaved cas-
pase 3, caspase 9 and PARP were examined by western
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blot analysis. Forskolin induced profound cleavage of
caspase 9, caspase 3 and PARP in INA-6 cells, and to a
lesser extent in MOPC315 cells (Figure 4B), confirming
that cAMP indeed kills human and murine multiple
myeloma cells by activating the apoptotic machinery
cAMP delays growth of multiple myeloma cells in vivo
Having shown that elevation of intracellular cAMP kills
multiple myeloma cells in vitro, we explored the
therapeutic potential of cAMP-elevating compounds on
tumor growth in vivo, taking advantage of a previously
established mouse model for multiple myeloma based
on subcutaneous injection of MOPC315 cells [24] pre-
labeled with the fluorescent protein DsRed [34]. BALB/c
nude mice were subcutaneously injected between the
shoulders with 5 × 105 MOPC315 cells stably trans-
fected with the gene encoding the fluorescent protein
DsRed (MOPC315.DsRed cells). Two days after
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inoculation of the cells, 5 mice were intraperitoneally
injected with a single dose of forskolin (4-5 mg/kg),
whereas 5 mice were injected with the same volume of
vehicle. Tumor size was followed daily by in vivo ima-
ging of DsRed fluorescence using an IVIS Spectrum
Imaging System from Caliper Life Sciences. All 10 mice
eventually developed tumors, but a single dose of for-
skolin substantially delayed the tumor growth in vivo
(Figure 5A). Similar results were obtained in a separate
experiment where mice were injected 3 times with for-
skolin or vehicle on days 2, 4, and 6 after tumor cells
injection (Figure 5B). Statistical differences between
vehicle treated and forskolin treated mice is achieved (p
< 0.05) from day 6 after tumor cell injection. Figure 5C
shows in vivo images of mice taken at day 7. Together,
these results suggest that cAMP-elevating compounds
may indeed have a therapeutic potential in treatment of
multiple myeloma.
Discussion
We have demonstrated that intracellular elevation of
cAMP levels efficiently kills both murine and human
multiple myeloma cells in vitro, and that the cAMP-ele-
vating compound forskolin markedly delays the in vivo
growth of multiple myeloma cells in a mouse model.
Modulation of intracellular cAMP by directly increas-
ing the level of cAMP in the cell or by inhibiting PDE
has become an interesting approach to cancer therapy
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Figure 5 Forskolin delays tumor growth in vivo. Ten BALB/c Nude mice were subcutaneously injected with 5 × 105 MOP315.DsRed cells on
day 0. On day 2 (panels A), groups of 5 mice received an intraperitoneal injection of forskolin (4-5 mg/kg) or vehicle. In a separate experiment
(panel B), 5 mice received 3 subsequent injections with forskolin or vehicle on days 2, 4 and 6. In vivo imaging of DsRed fluorescence from the
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represent SEM. *P < 0.05 relative to vehicle treated mice. (C) In vivo images of individual mice taken at day 7 from the one injection experiment
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[16,35,36 for reviews]. In a phase-II study, theophylline,
a methylxanthine that inhibits PDEs, proved to be effec-
tive in patients with chronic lymphocytic leukemia [37].
Activation of the cAMP pathways may either induce or
inhibit cell proliferation or cell death depending on the
cell type, and from our own research it is clear that the
effect of cAMP also varies between different types of
lymphoid cells. Thus, whereas elevation of intracellular
cAMP inhibits DNA-damage induced apoptosis and p53
stabilization in BCP-ALL cells and normal B- and T
cells [20], no such effects were seen in myeloma cells. It
is possible that the inability of cAMP to prevent the IR-
induced stabilization of p53 in myeloma cells could
explain why cAMP is unable to counteract IR-mediated
apoptosis in these cells.
Why myeloma cells and not BCP-ALL cells are so effi-
ciently killed by solely elevating the level of cAMP is,
however, unclear. The different players in the cAMP sig-
naling pathway are highly compartmentalized in the
cells, with G-coupled receptors, adenylyl cyclases, PKAs,
Epacs, and phosphodiesterases all being brought in close
proximity in distinct signalosomes within the cells [38].
It is possible that the activity of distinct signalosomes
might contribute to localized, yet physiological signifi-
cant differences in response to activating the cAMP sig-
nal in different lymphoid subpopulations. We also
observed variations in the sensitivity to forskolin
between the different myeloma cell lines used. This
could presumably be due to variations in level and/or
activity of the various components of the cAMP/PKA
pathways in the different cell lines.
In an early paper [39], it was shown that cAMP ana-
logs including 8-chloro-cAMP, dibutyryl-cAMP and 8-
bromo-cAMP inhibited cell growth and induced cell
death in glucocorticoid sensitive and resistant multiple
myeloma cell lines. However, it was subsequently con-
cluded that 8-chloro-cAMP mediated the cytotoxicity
via its metabolite 8-chloro-adenosine (8Cl-AD) and not
via the cAMP pathway [40,41]. Therefore, the potential
for cAMP-elevating compounds in therapy of multiple
myeloma was not further pursued. Recently, however, in
an interesting study by Rickles and coworkers using a
high throughput screening (cHTS) platform to identify
new drugs to combine with existing therapeutic strate-
gies for multiple myeloma [42], it was discovered that
the agonist of the adenosine A2A receptor as well as
phosphodiesterase (PDE) inhibitors synergized with glu-
cocorticoids to inhibit cell proliferation and induce
death of multiple myeloma cells [42], thereby supporting
our present results.
A key finding in the present study was the novel demon-
stration of the ability of the cAMP elevating agent forsko-
lin to inhibit the in vivo growth of multiple myeloma cells
in a mouse model. It is not yet clear whether this reduced
tumor growth is due to induced tumor cell death. Tumors
eventually also developed in forskolin-treated mice, which
could be due to the outgrowth of a small portion of for-
skolin-resistant cells. Attempts to give 3 doses of forskolin
spaced 2 days apart did not markedly improve the effect
on tumor growth compared to a single dose. A combina-
tion of cAMP-elevating compounds and conventional
therapeutic agents could probably improve the outcome.
The enhanced killing of myeloma cells we observed in
vitro by combining forskolin and g-irradiation supports
this strategy. Based on the findings by Rickles et al [42], it
will also be interesting to test the combination of cAMP
elevating agents, phosphodiesterase inhibitors and gluco-
corticoids on the in vivo growth of multiple myeloma
cells. It is clear that the potential for cAMP in the field of
multiple myeloma is revitalized.
Conclusion
Stimulation of the cAMP-signaling pathway not only
kills human and murine multiple myeloma cells in vitro,
but it also reduces in vivo growth of multiple myeloma
cells in a mouse model. Elevation of cAMP kills the
cells via classical apoptotic mechanisms involving mito-
chondrial membrane-changes and activation of caspases.
These results support the potential use of cAMP elevat-
ing agents as targets against multiple myeloma.
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